BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18705570)

  • 1. Receptor characteristics of the second tumor in synchronous versus metachronous breast cancer.
    Bu-Ali H; Solh M; Kapur A; Mittal V
    Am Surg; 2008 Aug; 74(8):702-5; discussion 706. PubMed ID: 18705570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral Breast Cancer After Multimodality Treatment: A Report of Clinical Outcomes in an Asian Population.
    Wadasadawala T; Lewis S; Parmar V; Budrukkar A; Gupta S; Nair N; Shet T; Badwe R; Sarin R
    Clin Breast Cancer; 2018 Aug; 18(4):e727-e737. PubMed ID: 29254601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of synchronous and metachronous bilateral breast cancer.
    Kollias J; Ellis IO; Elston CW; Blamey RW
    World J Surg; 2001 Sep; 25(9):1117-24. PubMed ID: 11571945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synchronous and metachronous bilateral breast cancer: A long-term experience.
    Ozturk A; Alco G; Sarsenov D; Ilgun S; Ordu C; Koksal U; Nur Pilanci K; Erdogan Z; Izci F; Elbuken F; Agacayak F; Aktepe F; Ozmen V
    J BUON; 2018; 23(6):1591-1600. PubMed ID: 30610782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bilateral breast carcinoma. 12 years' experience].
    Maculotti L; Gandini F; Pradella P
    Minerva Chir; 1996; 51(1-2):33-7. PubMed ID: 8677043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours.
    Carmichael AR; Bendall S; Lockerbie L; Prescott R; Bates T
    Eur J Surg Oncol; 2002 Jun; 28(4):388-91. PubMed ID: 12099647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral breast cancer: differential diagnosis using histological and biological parameters.
    Gong SJ; Rha SY; Jeung HC; Roh JK; Yang WI; Chung HC
    Jpn J Clin Oncol; 2007 Jul; 37(7):487-92. PubMed ID: 17673471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease.
    Heron DE; Komarnicky LT; Hyslop T; Schwartz GF; Mansfield CM
    Cancer; 2000 Jun; 88(12):2739-50. PubMed ID: 10870056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of bilateral breast cancer on prognosis: synchronous versus metachronous tumors.
    Ibrahim NY; Sroor MY; Darwish DO
    Asian Pac J Cancer Prev; 2015; 16(3):1007-10. PubMed ID: 25735321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features in bilateral breast cancer.
    Baykara M; Ozturk SC; Buyukberber S; Helvaci K; Ozdemir N; Alkis N; Berk V; Koca D; Coskun U; Oksuzoglu B; Uncu D; Arpaci E; Ustaalioglu BO; Demirci U; Kucukoner M; Dogu GG; Alici S; Akman T; Ozkan M; Aslan UY; Durnali AG; Benekli M
    Asian Pac J Cancer Prev; 2012; 13(9):4571-5. PubMed ID: 23167382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
    Senkus E; Szade J; Pieczyńska B; Zaczek A; Pikiel J; Sosińska-Mielcarek K; Karpińska A; Jassem J
    Int J Clin Exp Pathol; 2014; 7(1):353-63. PubMed ID: 24427357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer.
    Ding S; Sun X; Lu S; Wang Z; Chen X; Shen K
    Breast; 2021 Jun; 57():71-79. PubMed ID: 33774461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma.
    Matsuo K; Fukutomi T; Tsuda H; Akashi-Tanaka S; Shimizu C; Hasegawa T
    J Surg Oncol; 2001 May; 77(1):31-4. PubMed ID: 11344480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer.
    Heaton KM; Peoples GE; Singletary SE; Feig BW; Ross MI; Ames FC; Buchholz TA; Strom EA; McNeese MD; Hunt KK
    Ann Surg Oncol; 1999; 6(1):102-8. PubMed ID: 10030422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Shoji F; Yamashita N; Inoue Y; Kozuma Y; Toyokawa G; Hirai F; Ito K; Tagawa T; Okamoto T; Maehara Y
    Anticancer Res; 2017 Oct; 37(10):5871-5876. PubMed ID: 28982914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries.
    Kurzyński M; Mituś J; Kołodziej-Rzepa M; Sas-Korczyńska B
    Ginekol Pol; 2018; 89(5):235-239. PubMed ID: 30084474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Breast carcinoma in the man. Current results from the viewpoint of clinic and pathology].
    Prechtel K; Prechtel V
    Pathologe; 1997 Jan; 18(1):45-52. PubMed ID: 9157404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance in histological and biological parameters between first and second primary breast cancers.
    Huo D; Melkonian S; Rathouz PJ; Khramtsov A; Olopade OI
    Cancer; 2011 Mar; 117(5):907-15. PubMed ID: 20945326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral renal cancers: oncological and functional outcomes.
    Berczi C; Thomas B; Bacso Z; Flasko T
    Int Urol Nephrol; 2016 Oct; 48(10):1617-22. PubMed ID: 27379623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
    Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
    Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.